Form 4 for TARS Tarsus Pharmaceuticals, Inc.
Accepted 2026-03-17 00:00:00 ET · period of report 2026-03-15 · accession 0001788542-26-000005 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-03-17 | 2026-03-15 | TARS | Mottiwala Aziz | Chief Commercial Off | M - OptEx | — | +26.5K | 74.5K | +55% | — |
| DM | 2026-03-17 | 2026-03-15 | TARS | Mottiwala Aziz | Chief Commercial Off | M - OptEx | $0.00 | -26.5K | 16.6K | -62% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-03-15 | M | A | 26,482 | — | 74,536 | D | — | — | (F1) The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). (F2) Includes 497 shares acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2025 and December 31, 2025. |
| 2 | Derivative | Restricted Stock Units | 2026-03-15 | M | D | 4,790 | $0.00 | 0 | D | — · — to — | 4,790 Common Stock | (F3) Each Restricted Stock Unit represents a contingent right to receive one share of the Company's common stock. (F4) RSUs granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs vested on March 15th of each of 2023, 2024, 2025 and 2026. |
| 3 | Derivative | Restricted Stock Units | 2026-03-15 | M | D | 8,148 | $0.00 | 8,148 | D | — · — to — | 8,148 Common Stock | (F3) Each Restricted Stock Unit represents a contingent right to receive one share of the Company's common stock. (F5) RSUs granted on March 8, 2023, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2024, 2025, 2026 and 2027, subject to the Reporting Person's continuous service. |
| 4 | Derivative | Restricted Stock Units | 2026-03-15 | M | D | 8,020 | $0.00 | 16,040 | D | — · — to — | 8,020 Common Stock | (F3) Each Restricted Stock Unit represents a contingent right to receive one share of the Company's common stock. (F6) RSUs granted on March 7, 2024, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2025, 2026, 2027 and 2028, subject to the Reporting Person's continuous service. |
| 5 | Derivative | Restricted Stock Units | 2026-03-15 | M | D | 5,524 | $0.00 | 16,574 | D | — · — to — | 5,524 Common Stock | (F3) Each Restricted Stock Unit represents a contingent right to receive one share of the Company's common stock. (F7) RSUs granted on March 5, 2025, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2026, 2027, 2028 and 2029, subject to the Reporting Person's continuous service. |